SCHEMBL1446948

SCHEMBL1446948

Cc1c(C)c(C)[n+]([O-])c(Br)c1-c1nc(-c2cc(O)c(O)c([N+](=O)[O-])c2)no1

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.64
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 3/20 0.37
POLB P06746 4/20 0.37
TP53 P04637 1/20 0.37
ERN1 O75460 1/20 0.36
GAA P10253 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1447117 0.94 COMT (0.69) COMTNPC1RAB9AMAPTPOLB
SCHEMBL1446764 0.91 COMT (0.78) COMTNPC1RAB9AMAPTPOLB
SCHEMBL1447793 0.88 COMT (0.75) COMTNPC1RAB9AMAPTPOLB
SCHEMBL1447181 0.85 COMT (0.84) COMTNPC1RAB9AMAPTPOLB
SCHEMBL1447042 0.85 COMT (0.87) COMTNPC1RAB9AMAPTPOLB
SCHEMBL1446763 0.84 COMT (0.53) COMTRAB9AMAPTPOLBERN1
SCHEMBL1446344 0.83 COMT (0.51) COMTMAPTERN1MAPK1
SCHEMBL1446724 0.83 COMT (0.52) COMTMAPTERN1MAPK1
SCHEMBL3587510 0.82 COMT (0.56) COMTNPC1RAB9AMAPTPOLB
SCHEMBL1448331 0.82 COMT (0.66) COMTNPC1RAB9AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2022-12-08 US disclosed
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2020-04-02 US disclosed
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2019-07-02 US disclosed
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & COMPANHIA, S.A. (PT) 2017-12-21 US disclosed
US-9550759-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2017-01-24 US disclosed
EP-1907382-B1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2015-05-27 EP disclosed
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2015-03-12 US disclosed
US-8907099-B2 Nitrocatechol derivatives as COMT inhibitors BIAL-PORTELA & CA, S.A. (PT) 2014-12-09 US disclosed
EP-2672973-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS Bial-Portela & CA, S.A. (PT) 2013-12-18 EP disclosed
WO-2012107708-A9 ADMINISTRATION REGIME FOR NITROCATECHOLS BIAL - PORTELA & CA, S.A. (PT) 2013-02-14 WO disclosed
WO-2012107708-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS BIAL - PORTELA & CA, S.A. (PT) 2012-08-16 WO disclosed
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA., S.A. (PT) 2012-08-02 US disclosed
US-8168793-B2 Nitrocatechol derivatives as COMT inhibitors PORTELA & CA., S.A. (PT) 2012-05-01 US disclosed
EP-2307020-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS Bial-Portela & CA, S.A. (PT) 2011-04-13 EP disclosed
EP-2301934-A1 Nitrocatechol derivatives as COMT inhibitors BIAL - Portela & Ca., S.A. (PT) 2011-03-30 EP disclosed
WO-2010014025-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS BIAL - PORTELA & CA., S.A. (PT) 2010-02-04 WO disclosed
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors PORTELA & CA., S.A. (PT) 2009-02-26 US disclosed
EP-1907382-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS Portela & C.A. S.A (PT) 2008-04-09 EP disclosed
WO-2007013830-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA. S.A. (PT) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885NPC1 470/4885RAB9A 2248/4885
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885NPC1 470/4885RAB9A 2248/4885
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885NPC1 504/4885RAB9A 2264/4885
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors COMT, PNMT, OPRK1 COMT 1/4885NPC1 470/4885RAB9A 2248/4885
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors COMT, PNMT, OPRK1 COMT 1/4885NPC1 470/4885RAB9A 2248/4885
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885NPC1 504/4885RAB9A 2264/4885
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885NPC1 470/4885RAB9A 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.